Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

Business Wire November 12, 2019

Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference

Business Wire November 11, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire November 5, 2019

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Sage Therapeutics, Inc.- SAGE

GlobeNewswire October 30, 2019

Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Business Wire October 9, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 2, 2019

Sage Therapeutics to Participate in J.P. Morgan Executive Conference Call Series

Business Wire October 2, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire September 5, 2019

Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder

Business Wire September 4, 2019

Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 3, 2019

Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

Business Wire August 6, 2019

Sage Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

Business Wire August 5, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire August 5, 2019

Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline During "Sage FutureCast"

Business Wire July 24, 2019

Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019

Business Wire July 11, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire July 3, 2019

Sage Therapeutics to Host "Sage FutureCast" Webcast

Business Wire June 27, 2019

Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference

Business Wire June 18, 2019

Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO(TM) (brexanolone) Injection

Business Wire June 14, 2019

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire June 5, 2019